175 related articles for article (PubMed ID: 18283428)
1. Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study.
Horsdal HT; Johnsen SP; Søndergaard F; Rungby J
Diabetologia; 2008 Apr; 51(4):567-74. PubMed ID: 18283428
[TBL] [Abstract][Full Text] [Related]
2. Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study.
Horsdal HT; Johnsen SP; Søndergaard F; Jacobsen J; Thomsen RW; Schmitz O; Sørensen HT; Rungby J
Diabetes Metab Res Rev; 2009 Sep; 25(6):515-22. PubMed ID: 19459168
[TBL] [Abstract][Full Text] [Related]
3. Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study.
Horsdal HT; Mehnert F; Rungby J; Johnsen SP
J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):717-25. PubMed ID: 21536457
[TBL] [Abstract][Full Text] [Related]
4. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention--a retrospective nationwide cohort study.
Jørgensen CH; Gislason GH; Andersson C; Ahlehoff O; Charlot M; Schramm TK; Vaag A; Abildstrøm SZ; Torp-Pedersen C; Hansen PR
Cardiovasc Diabetol; 2010 Sep; 9():54. PubMed ID: 20843380
[TBL] [Abstract][Full Text] [Related]
5. Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial.
Ritsinger V; Malmberg K; Mårtensson A; Rydén L; Wedel H; Norhammar A
Lancet Diabetes Endocrinol; 2014 Aug; 2(8):627-33. PubMed ID: 24831989
[TBL] [Abstract][Full Text] [Related]
6. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study.
Kosiborod M; Birkeland KI; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Jørgensen ME; Wittbrodt ET; Thuresson M; Bodegård J; Hammar N; Fenici P;
Diabetes Obes Metab; 2018 Aug; 20(8):1983-1987. PubMed ID: 29569378
[TBL] [Abstract][Full Text] [Related]
7. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
8. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.
Schramm TK; Gislason GH; Køber L; Rasmussen S; Rasmussen JN; Abildstrøm SZ; Hansen ML; Folke F; Buch P; Madsen M; Vaag A; Torp-Pedersen C
Circulation; 2008 Apr; 117(15):1945-54. PubMed ID: 18378618
[TBL] [Abstract][Full Text] [Related]
9. Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study.
Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
Diabetologia; 2015 Jan; 58(1):50-8. PubMed ID: 25205223
[TBL] [Abstract][Full Text] [Related]
10. Long-term mortality in patients with type 2 diabetes undergoing coronary angiography: the impact of glucose-lowering treatment.
Saleh N; Petursson P; Lagerqvist B; Skúladóttir H; Svensson A; Eliasson B; Gudbjörnsdottir S; Eeg-Olofsson K; Norhammar A
Diabetologia; 2012 Aug; 55(8):2109-17. PubMed ID: 22566103
[TBL] [Abstract][Full Text] [Related]
11. Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study.
Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L;
Diabetologia; 2011 Jun; 54(6):1308-17. PubMed ID: 21359582
[TBL] [Abstract][Full Text] [Related]
12. Temporal trends in the initiation of glucose-lowering medications after a first-time myocardial infarction - a nationwide study between 1997 and 2006.
Norgaard ML; Andersson C; Hansen PR; Andersen SS; Vaag A; Schramm TK; Folke F; Køber L; Torp-Pedersen C; Gislason GH
Cardiovasc Diabetol; 2011 Jan; 10():5. PubMed ID: 21247456
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial.
Mellbin LG; Malmberg K; Waldenström A; Wedel H; Rydén L;
Heart; 2009 May; 95(9):721-7. PubMed ID: 19029171
[TBL] [Abstract][Full Text] [Related]
14. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.
Schramm TK; Gislason GH; Vaag A; Rasmussen JN; Folke F; Hansen ML; Fosbøl EL; Køber L; Norgaard ML; Madsen M; Hansen PR; Torp-Pedersen C
Eur Heart J; 2011 Aug; 32(15):1900-8. PubMed ID: 21471135
[TBL] [Abstract][Full Text] [Related]
15. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.
Malmberg K; Rydén L; Wedel H; Birkeland K; Bootsma A; Dickstein K; Efendic S; Fisher M; Hamsten A; Herlitz J; Hildebrandt P; MacLeod K; Laakso M; Torp-Pedersen C; Waldenström A;
Eur Heart J; 2005 Apr; 26(7):650-61. PubMed ID: 15728645
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
[TBL] [Abstract][Full Text] [Related]
17. A large frontal QRS-T angle is a strong predictor of the long-term risk of myocardial infarction and all-cause mortality in the diabetic population.
May O; Graversen CB; Johansen MØ; Arildsen H
J Diabetes Complications; 2017 Mar; 31(3):551-555. PubMed ID: 28065667
[TBL] [Abstract][Full Text] [Related]
18. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
[TBL] [Abstract][Full Text] [Related]
19. All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
Scheller NM; Mogensen UM; Andersson C; Vaag A; Torp-Pedersen C
Diabetes Obes Metab; 2014 Mar; 16(3):231-6. PubMed ID: 24020750
[TBL] [Abstract][Full Text] [Related]
20. No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives.
Gokhale M; Buse JB; Jonsson Funk M; Lund J; Pate V; Simpson RJ; Stürmer T
Diabetes Obes Metab; 2017 Jul; 19(7):970-978. PubMed ID: 28195389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
